Abstract
Recently identified novel agents that disrupt tubulin polymerization include synthetic spiroketal pyrans (SPIKET) targeting the spongistatin binding site of beta tubulin. These agents exhibit anticancer activity by disrupting normal mitotic spindle assembly and cell division as well as inducing apoptosis. At nanomolar concentrations, the SPIKET compound SPIKET-P caused tubulin depolymerization in cell-free turbidity assays and exhibited potent cytotoxic activity against cancer cells as evidenced by destruction of microtubule organization, and prevention of mitotic spindle formation in human breast cancer cells. SPIKET compounds represent a new class of tubulin targeting agents that show promise as anti-cancer drugs.
Keywords: Spongistatins, Tubulin Targeting Agents, spiroketal pyrans (SPIKET), anticancer activity, SPIKET, SPIKET-P, anti-cancer drugs, Spiroketal Pyrans (SPIKET-P), Beta Tubulin, colchicine
Current Pharmaceutical Design
Title: Spongistatins as Tubulin Targeting Agents
Volume: 7 Issue: 13
Author(s): F. M. Uckun, C. Mao, S. -T. jan, H. Huang, A. O. Vassilev, C. S. Navara and R. K. Narla
Affiliation:
Keywords: Spongistatins, Tubulin Targeting Agents, spiroketal pyrans (SPIKET), anticancer activity, SPIKET, SPIKET-P, anti-cancer drugs, Spiroketal Pyrans (SPIKET-P), Beta Tubulin, colchicine
Abstract: Recently identified novel agents that disrupt tubulin polymerization include synthetic spiroketal pyrans (SPIKET) targeting the spongistatin binding site of beta tubulin. These agents exhibit anticancer activity by disrupting normal mitotic spindle assembly and cell division as well as inducing apoptosis. At nanomolar concentrations, the SPIKET compound SPIKET-P caused tubulin depolymerization in cell-free turbidity assays and exhibited potent cytotoxic activity against cancer cells as evidenced by destruction of microtubule organization, and prevention of mitotic spindle formation in human breast cancer cells. SPIKET compounds represent a new class of tubulin targeting agents that show promise as anti-cancer drugs.
Export Options
About this article
Cite this article as:
Uckun M. F., Mao C., jan -T. S., Huang H., Vassilev O. A., Navara S. C. and Narla K. R., Spongistatins as Tubulin Targeting Agents, Current Pharmaceutical Design 2001; 7 (13) . https://dx.doi.org/10.2174/1381612013397492
DOI https://dx.doi.org/10.2174/1381612013397492 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expression Profiling of Estrogen Responsive Genes Using Genomic and Proteomic Techniques for the Evaluation of Endocrine Disruptors
Current Pharmacogenomics Bioactive Herbal Alkaloids as Anti-Infective Agents
Anti-Infective Agents Plasma Infusions into Porcine Cerebral White Matter Induce Early Edema, Oxidative Stress, Pro-Inflammatory Cytokine Gene Expression and DNA Fragmentation: Implications for White Matter Injury with Increased Blood- Brain-Barrier Permeability
Current Neurovascular Research Bitter Gourd (Momordica charantia) is a Cornucopia of Health: A Review of its Credited Antidiabetic, Anti-HIV, and Antitumor Properties
Current Molecular Medicine Elucidation of the Chemopreventive Role of Stigmasterol Against Jab1 in Gall Bladder Carcinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Molecular Basis of Therapeutic Strategies for Breast Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Intestinal Microbiota: A Regulator of Intestinal Inflammation and Cardiac Ischemia?
Current Drug Targets Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer
Current Pharmaceutical Design Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression
Current Cancer Drug Targets Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Innovations and Improvements in Pharmacokinetic Models Based on Physiology
Current Drug Delivery Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies
Current Medicinal Chemistry Circulating Exosomes as Potential Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Routine Collection of Patient-Reported Outcomes in an HIV Clinic Setting:The First 100 Patients
Current HIV Research Human Disease Modelling Techniques: Current Progress
Current Molecular Medicine Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes
Current Bioinformatics Cancer Therapy-Induced Residual Bone Marrow Injury: Mechanisms of Induction and Implication for Therapy
Current Cancer Therapy Reviews